The world's scientific and social network for malaria professionals
Subscribe to free Newsletter | 10625 malaria professionals are enjoying the free benefits of MalariaWorld today

S/AS01

The Clinical Profile of Severe Pediatric Malaria in an Area Targeted for Routine RTS,S/AS01 Malaria Vaccination in Western Kenya

July 16, 2020 - 08:06 -- Open Access
Author(s): 
Akech S, Chepkirui M, Ogero M, Agweyu A, Irimu G, English M, Snow RW
Reference: 
Clin Infect Dis. 2020 Jul 11;71(2):372-380

The malaria prevalence has declined in western Kenya, resulting in the risk of neurological phenotypes in older children. This study investigates the clinical profile of pediatric malaria admissions ahead of the introduction of the RTS,S/AS01 vaccine.

The thermostability of the RTS,S/AS01 malaria vaccine can be increased by co-lyophilizing RTS,S and AS01

June 9, 2020 - 16:05 -- Open Access
Author(s): 
Juliette Fortpied, Sylvie Collignon, Nicolas Moniotte, Frédéric Renaud, Babak Bayat and Dominique Lemoine
Reference: 
Malaria Journal 2020 19:202, 8 June 2020

Developing thermostable vaccines is a challenge for pharmaceutical companies due to the inherent instability of biological molecules in aqueous solution. The problem is even more stringent in regions subjected to high temperatures in which protective cold chain is difficult to maintain due to a lack of infrastructure. Here, a simple, cost-effective solution to increase the thermostability of the malaria candidate vaccine RTS,S/AS01 is described. This vaccine currently needs to be stored between 2 and 8  °C due to the sensitivity of liquid AS01 to higher temperatures. The strategy was to increase thermostability by co-lyophilizing the RTS,S antigen and AS01.

NOT Open Access | Case reduction and cost-effectiveness of the RTS,S/AS01 malaria vaccine alongside bed nets in Lilongwe, Malawi

May 6, 2020 - 15:39 -- NOT Open Access
Author(s): 
Bell GJ, Loop M, Emch M, et al.
Reference: 
Vaccine. 2020 Apr 30. pii: S0264-410X(20)30511-9

RTS,S/AS01, the most advanced vaccine against malaria, is now undergoing pilot implementation in Malawi, Ghana, and Kenya where an estimated 360,000 children will be vaccinated each year. In this study we evaluate RTS,S/AS01 alongside bed net use and estimate cost-effectiveness.

Safety and immunogenicity of the RTS,S/AS01 malaria vaccine in infants and children identified as HIV-infected during a randomized trial in sub-Saharan Africa

January 24, 2020 - 14:40 -- Open Access
Author(s): 
Otieno L, Guerra Mendoza Y, Oneko M, et al.
Reference: 
Vaccine Volume 38, Issue 4, 22 January 2020, Pages 897-906

We assessed the safety and immunogenicity of the RTS,S/AS01 malaria vaccine in a subset of children identified as HIV-infected during a large phase III randomized controlled trial conducted in seven sub-Saharan African countries.

Subscribe to RSS - S/AS01